News

Becker's Hospital Review1d
After patient’s death, study cites potential barrier to Elevidys
A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...
FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients
The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...
Healio9d
Tirzepatide improves outcomes in HFpEF, obesity regardless of kidney function
In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...
Medical Xpress9d
Open-heart bypass surgery and less invasive procedure show similar outcomes in heart disease study
"At five years after random assignment to either PCI or CABG, we found no significant differences between the two groups in the primary endpoint—a composite of death, stroke or heart attack." ...
Morningstar9d
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
ROSELLA has dual primary endpoints — PFS-BICR and OS. A positive outcome is achieved if either endpoint is met ... fifth most common cause of cancer death in women. Patients whose disease ...
Medscape6d
Real-World Anifrolumab Use Shows Evidence of Long-Term Organ Damage Reduction in Lupus
Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...
PharmExec5d
Winrevair Found to Significantly Reduce the Risk of Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension
Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...
BioCardia’s CardiAMP-HF trial primary endpoint did not reach significance
BioCardia (BCDA) announced two-year outcomes from the double-blind randomized placebo-controlled Phase 3 CardiAMP-HF study of its CardiAMP ...